Dow Jones

42,732.13

0.80%

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
UK
LSE
Roche Holding Ag (0QQ6)
Roche Holding Ag (0QQ6) News

Roche (0QQ6)

Roche Holding Ag

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0QQ6

1 2 3 Next >>

Date	Time	Source	Headline	Symbol	Company
19/12/2024	06:00	UK Regulatory	Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease	LSE:0QQ6	Roche Holding Ag
18/12/2024	06:00	UK Regulatory	Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution	LSE:0QQ6	Roche Holding Ag
13/12/2024	06:10	UK Regulatory	Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness	LSE:0QQ6	Roche Holding Ag
13/12/2024	06:00	UK Regulatory	Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities	LSE:0QQ6	Roche Holding Ag
10/12/2024	06:00	UK Regulatory	New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma	LSE:0QQ6	Roche Holding Ag
09/12/2024	21:30	UK Regulatory	Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash	LSE:0QQ6	Roche Holding Ag
08/12/2024	17:30	UK Regulatory	Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma	LSE:0QQ6	Roche Holding Ag
05/12/2024	06:00	UK Regulatory	FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma	LSE:0QQ6	Roche Holding Ag
26/11/2024	06:10	UK Regulatory	Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies	LSE:0QQ6	Roche Holding Ag
26/11/2024	06:00	UK Regulatory	Roche reports update on Phase III SKYSCRAPER-01 study results	LSE:0QQ6	Roche Holding Ag
05/11/2024	14:15	UK Regulatory	Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024	LSE:0QQ6	Roche Holding Ag
31/10/2024	06:15	UK Regulatory	Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease	LSE:0QQ6	Roche Holding Ag
31/10/2024	06:00	UK Regulatory	New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer	LSE:0QQ6	Roche Holding Ag
23/10/2024	09:58	IH Market News	US Futures Fall Amid Treasury Yield Surge and Earnings; Oil Prices Dip as U.S. Crude Inventories Rise	LSE:0QQ6	Roche Holding Ag
23/10/2024	05:00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months	LSE:0QQ6	Roche Holding Ag
23/10/2024	05:00	UK Regulatory	[Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6%	LSE:0QQ6	Roche Holding Ag
18/10/2024	21:00	UK Regulatory	Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study	LSE:0QQ6	Roche Holding Ag
14/10/2024	05:00	UK Regulatory	Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate	LSE:0QQ6	Roche Holding Ag
11/10/2024	05:00	UK Regulatory	FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	LSE:0QQ6	Roche Holding Ag
10/10/2024	05:00	UK Regulatory	Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY	LSE:0QQ6	Roche Holding Ag
26/09/2024	05:00	UK Regulatory	Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis	LSE:0QQ6	Roche Holding Ag
24/09/2024	05:00	UK Regulatory	Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses	LSE:0QQ6	Roche Holding Ag
23/09/2024	05:00	UK Regulatory	WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions	LSE:0QQ6	Roche Holding Ag
19/09/2024	05:00	UK Regulatory	Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses	LSE:0QQ6	Roche Holding Ag
16/09/2024	05:00	UK Regulatory	FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis	LSE:0QQ6	Roche Holding Ag
13/09/2024	05:00	UK Regulatory	FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy	LSE:0QQ6	Roche Holding Ag
10/09/2024	14:00	UK Regulatory	Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen	LSE:0QQ6	Roche Holding Ag
10/09/2024	14:00	UK Regulatory	Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation	LSE:0QQ6	Roche Holding Ag
04/09/2024	06:00	UK Regulatory	Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis	LSE:0QQ6	Roche Holding Ag
27/08/2024	05:00	UK Regulatory	Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH	LSE:0QQ6	Roche Holding Ag